Skip to content

Clinical and Radiographic Evaluation of Zinc Oxide-Propolis Mixture Versus Modified Triple Antibiotic Paste in LSTR

Clinical and Radiographic Evaluation of Zinc Oxide-Propolis Mixture Versus Modified Triple Antibiotic Paste in Lesion Sterilization and Tissue Repair (LSTR) for the Treatment of Necrotic Primary Molars: A Randomized Clinical Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06158451
Enrollment
40
Registered
2023-12-06
Start date
2024-03-01
Completion date
2025-01-31
Last updated
2024-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative, Periapical; Infection

Keywords

propolis, modified triple antibiotic paste, lesion sterilization and tissue repair

Brief summary

The aim of this study is to evaluate and compare the clinical effectiveness of zinc oxide-propolis mixture with triple antibiotic paste in LSTR as root canal filling material in necrotic primary molars.

Detailed description

The promising results of propolis as a natural antibiotic in previous in- vivo studies made it interesting to combine propolis to the golden standard zinc oxide eugenol as an intracanal medication in pulp affected primary molars and use this mix as a natural substitute to the modified triple antibiotic paste (m-TAP) and therefore overcoming the antibiotic bacterial resistance, allergy and developmental anomalies that might arise in permanent successor teeth from m-TAP usage.

Interventions

COMBINATION_PRODUCTZinc oxide propolis

Propolis liquid (Brazilian Green Bee Propolis Liquid Extract, Uniflora®) and Zinc oxide powder will be mixed on a glass slab with the help of a stainless -steel spatula. • The mixing ratio of zinc oxide powder and Propolis liquid is 2:1 until a paste like consistency is reached.

Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals, Egypt,), and clindamycin capsules 300 mg(Dalacin C™ Pfizer, Egypt). * After the removal of enteric coating of tablets with the help of blade, the drugs are pulverized into fine powder using sterilized mortar and pestle. * The same amount of each powdered drug (1:1:1) is mixed to form m-TAP powder which is mixed with one part of propylene glycol (P) and the same volume of macrogol (M) to form a paste like consistency

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Double

Eligibility

Sex/Gender
ALL
Age
4 Years to 7 Years
Healthy volunteers
Yes

Inclusion criteria

* Children: 1. Cooperative children aged 4 -7 years old. 2. Systemically healthy. * Teeth: Clinical criteria: 1. Necrotic primary mandibular second molar teeth. 2. Spontaneous pain or tenderness to percussion 3. Deep carious lesion with pulp exposure. 4. Presence of chronic apical abscess or sinus tract Tooth should be restorable. (Thakur et al., 2021) Radiographic criteria: 1. Coronal-radiographic evidence of a deep carious lesions or lesion approximating pulp 2. Radicular discontinuity of lamina dura, furcation involvement less than or equal to half of shortest root in vertical dimension. (Thakur et al., 2021)

Exclusion criteria

* Children: 1. With physical or emotional alteration. 2. Children with systemic disease. 3. Previous history of allergy to antibiotics used in the study. 4. Children that will not attend follow up. • Teeth: <!-- --> 1. Non restorable carious primary molars. 2. Grade III mobility

Design outcomes

Primary

MeasureTime frameDescription
Postoperative pain1 yearBinary outcome measured with direct questioning to the patient
Tenderness to percussion1 year(binary outcome measured by percussion test using back of the dental mirror
Swelling / sinus tract1 yearbinary outcome measured with visual examination of the patient examination of the patient
Mobility1 year(measured by mobility test) and according to Miller's Grades; reduction in grade of mobility from preoperative baseline was treated as success

Secondary

MeasureTime frameDescription
Radiographic success6 monthsThe amount of furcation / periapical radiolucency in comparison to preoperative remained static or decreased

Contacts

Primary ContactSara Kh Adam, Master
sara.khaled@dentistry.cu.edu.eg01221709929

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026